These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 25721504)

  • 1. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.
    Perry RJ; Zhang D; Zhang XM; Boyer JL; Shulman GI
    Science; 2015 Mar; 347(6227):1253-6. PubMed ID: 25721504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
    Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
    FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.
    Goedeke L; Peng L; Montalvo-Romeral V; Butrico GM; Dufour S; Zhang XM; Perry RJ; Cline GW; Kievit P; Chng K; Petersen KF; Shulman GI
    Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained-release mitochondrial protonophore reverses nonalcoholic fatty liver disease in rats.
    Wei G; Song X; Fu Y; Gong T; Zhang Q
    Int J Pharm; 2017 Sep; 530(1-2):230-238. PubMed ID: 28754512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.
    Verbeek J; Lannoo M; Pirinen E; Ryu D; Spincemaille P; Vander Elst I; Windmolders P; Thevissen K; Cammue BP; van Pelt J; Fransis S; Van Eyken P; Ceuterick-De Groote C; Van Veldhoven PP; Bedossa P; Nevens F; Auwerx J; Cassiman D
    Gut; 2015 Apr; 64(4):673-83. PubMed ID: 24917551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.
    Sunny NE; Kalavalapalli S; Bril F; Garrett TJ; Nautiyal M; Mathew JT; Williams CM; Cusi K
    Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E311-9. PubMed ID: 26058864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease.
    Koliaki C; Roden M
    Mol Cell Endocrinol; 2013 Oct; 379(1-2):35-42. PubMed ID: 23770462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
    Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
    Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease.
    Grattagliano I; Montezinho LP; Oliveira PJ; Frühbeck G; Gómez-Ambrosi J; Montecucco F; Carbone F; Wieckowski MR; Wang DQ; Portincasa P
    Biochem Pharmacol; 2019 Feb; 160():34-45. PubMed ID: 30508523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAFLD and diabetes mellitus.
    Tilg H; Moschen AR; Roden M
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):32-42. PubMed ID: 27729660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence?
    García-Ruiz C; Baulies A; Mari M; García-Rovés PM; Fernandez-Checa JC
    Free Radic Res; 2013 Nov; 47(11):854-68. PubMed ID: 23915028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.